Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis

Richard LeBlanc, Hira Mian, Donna Reece, Jiandong Su, Esther Masih-Khan, Michael Chu, Victor Jimenez-Zepeda, Michael Sebag, Kevin Song, Martha Louzada, Rami Kotb, Alissa Visram, Darrell White, Julie Stakiw, Antony Reiman, Muhammad Aslam, Debra Bergstrom, Rayan Kaedbey, Engin Gul, Christopher Venner

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)815-823
Number of pages9
JournalEuropean Journal of Haematology
Volume111
Issue number5
DOIs
Publication statusPublished - Nov 2023

ASJC Scopus Subject Areas

  • Hematology

Keywords

  • carfilzomib
  • multiple myeloma
  • pomalidomide
  • post-daratumumab
  • real-world data

Fingerprint

Dive into the research topics of 'Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis'. Together they form a unique fingerprint.

Cite this

LeBlanc, R., Mian, H., Reece, D., Su, J., Masih-Khan, E., Chu, M., Jimenez-Zepeda, V., Sebag, M., Song, K., Louzada, M., Kotb, R., Visram, A., White, D., Stakiw, J., Reiman, A., Aslam, M., Bergstrom, D., Kaedbey, R., Gul, E., & Venner, C. (2023). Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European Journal of Haematology, 111(5), 815-823. https://doi.org/10.1111/ejh.14082